Antifungal sordaricin derivatives

US6645960B1 · kind B1 · utility

Assignee

• Glaxo Wellcome S.A. · ES

Inventors

• Jose M. Fiandor · Madrid, ES
• Sophie Huss · Madrid, ES

Key dates

• Filing date: Sep 24, 2002
• Grant date: Nov 11, 2003
• Expiry date: Sep 24, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of general formula (I) and physiologically acceptable salts wherein R represents phthalidyl, (2-oxo-5-methyl-1,3-diox-olen-4-yl)methyl or the group CHR4 OCO(O)pR5 wherein R4 is hydrogen or C1-4 alcyl, p is zero or I, R5 is C1-6 alkly, C5-8 cycloalyl (optionally substituted by C1-3 alkyl or carboxyl), C1-4 alkyl substituted by C1-3 alkoxy or carboxy), C1-4 alkyl substituted by one or more groups selected from amino, (C1-4 alkylamino di(C1-4 alkyl)amino or carboxyl, phenyl (optionally substituted by carboxyl or aminoalkyl, C1-4 alkylaminoalkyl or di(C1-4 alkyl)aminoalcyl, or R5 is a 5-8 membered heterocyclic group containing 1 or 2 heteroatoms selected from oxygen or nitrogen, processes for their preparation, pharmaceutical compositions containing them and their use in medicine.